| 101 |
23613014 | Decreased permeability surface area for glucose in obese women with postprandial hyperglycemia: no effect of phosphodiesterase-5 (PDE-5) inhibition. | 2013 Aug |
2 |
| 102 |
23656343 | Phosphodiesterase inhibitors in clinical urology. | 2013 May |
1 |
| 103 |
23765639 | PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. | 2013 Sep |
1 |
| 104 |
23804703 | Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. | 2013 Sep |
3 |
| 105 |
23876588 | Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. | 2013 Sep |
2 |
| 106 |
23917809 | Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. | 2013 Oct |
1 |
| 107 |
23949822 | Tadalafil for benign prostatic hyperplasia. | 2013 Aug |
2 |
| 108 |
24180640 | The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study. | 2013 Nov 25 |
10 |
| 109 |
24419925 | [Use of 5-phosphodiesterase inhibitors in patients with LUTS secondary to BPH: our experience and review of the literature]. | 2013 Sep-Dec |
1 |
| 110 |
24432631 | [Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction]. | 2013 Dec |
2 |
| 111 |
26558086 | Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. | 2013 Sep |
1 |
| 112 |
22156704 | Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? | 2012 |
2 |
| 113 |
22304626 | Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. | 2012 Apr |
1 |
| 114 |
22377518 | Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs. | 2012 Apr 1 |
1 |
| 115 |
22707162 | Identification of phototransformation products of sildenafil (Viagra) and its N-demethylated human metabolite under simulated sunlight. | 2012 Jun |
2 |
| 116 |
22725705 | Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. | 2012 Jul |
4 |
| 117 |
22759598 | Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. | 2012 Sep |
1 |
| 118 |
22947364 | The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. | 2012 Sep |
1 |
| 119 |
23033484 | Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6. | 2012 Nov 30 |
3 |
| 120 |
23117589 | Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel β-carboline derivatives. | 2012 Nov |
1 |
| 121 |
23297507 | [Tadalafil rehabilitation therapy for erectile dysfunction following prostatectomy]. | 2012 Oct |
1 |
| 122 |
24779692 | Determination of PDE-5 inhibitors and appetite suppressants in adulterated dietary supplements using LC/PDA and LC/MS. | 2012 |
1 |
| 123 |
26676704 | Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms. | 2012 Mar |
2 |
| 124 |
20704642 | Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). | 2011 Jan |
1 |
| 125 |
20859794 | Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. | 2011 |
2 |
| 126 |
21054754 | Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. | 2011 Jun |
1 |
| 127 |
21194760 | Brachial artery flow mediated assessment: a tool to predict the response to chronic PDE5 inhibition with tadalafil in patients with erectile dysfunction. | 2011 Feb 3 |
1 |
| 128 |
21275598 | Leber's hereditary optic neuropathy precipitated by tadalafil use for erectile dysfunction. | 2011 Jan |
2 |
| 129 |
21284024 | Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. | 2011 Mar |
1 |
| 130 |
21384413 | Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors. | 2011 Mar |
2 |
| 131 |
21460862 | Prevalence and medical management of erectile dysfunction in Asia. | 2011 Jul |
1 |
| 132 |
21504142 | Drug to genome to drug: discovery of new antiplasmodial compounds. | 2011 May 12 |
1 |
| 133 |
21585174 | The management of erectile dysfunction: innovations and future perspectives. | 2011 Mar |
1 |
| 134 |
21620965 | Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding. | 2011 Oct |
2 |
| 135 |
21702653 | Tadalafil for the treatment of pulmonary arterial hypertension. | 2011 Jun |
2 |
| 136 |
21707928 | A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. | 2011 Sep |
2 |
| 137 |
21719226 | Development and validation of a GC/MS method for the determination of tadalafil in whole blood. | 2011 Nov 1 |
2 |
| 138 |
21762988 | Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. | 2011 Aug |
5 |
| 139 |
21768131 | Identify drug repurposing candidates by mining the protein data bank. | 2011 Jul |
1 |
| 140 |
21771280 | Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. | 2011 Oct |
1 |
| 141 |
21812935 | Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. | 2011 Oct |
1 |
| 142 |
21914136 | Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study. | 2011 Sep-Oct |
3 |
| 143 |
21961252 | [Psychosomatic treatment: a key to the improvement of erectile dysfunction]. | 2011 Sep |
2 |
| 144 |
21995676 | Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. | 2011 Dec |
1 |
| 145 |
22131856 | Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. | 2011 Winter |
1 |
| 146 |
22469265 | Tadalafil. | 2011 |
1 |
| 147 |
23351473 | [Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension]. | 2011 |
2 |
| 148 |
19171388 | Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan. | 2010 Oct 29 |
1 |
| 149 |
19185976 | Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. | 2010 Mar |
2 |
| 150 |
19428174 | Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. | 2010 Apr |
2 |